CA
NZ
UK
AU
IND
US
• Acumen Pharmaceuticals (NASDAQ: ABOS) has drawn renewed market interest as Alzheimer’s research returns to focus.
• Vor Biopharma (NASDAQ: VOR) has seen a sharp move, reviving discussion about speculative interest in cell-therapy biotech.
• Fate Therapeutics (NASDAQ: FATE) has seen renewed market interest amid questions about improving cell-therapy sentiment.
• Foghorn Therapeutics (NASDAQ: FHTX) is attracting renewed attention as interest in precision medicine and gene-regulation drug development appears to broaden.
• Omeros (NASDAQ: OMER) has been drawing fresh market interest amid broader questions about whether sentiment toward biotech is improving.
• Carol Juel assumes leadership of Synchrony’s digital platform, combining executive‑vice‑president duties with chief‑executive responsibilities.
• Triller Group (NASDAQ: ILLR) disclosed a $300 million equity flexibility initiative in its latest shareholder communication.
• URSB Bancorp (OTC: URSB) named Michael L. Hammer to its board, with his term beginning in July 2026.
• Minerva Neurosciences (NASDAQ: NERV) has attracted renewed market interest amid attention on neuroscience-focused biotech.
• Cue Biopharma (NASDAQ: CUE) is a clinical-stage immunotherapy company that has drawn renewed market attention amid heightened trading activity.
Please wait processing your request...